Lymphocyte Doubling Time As A Key Prognostic Factor To Predict Time To First Treatment In Early-Stage Chronic Lymphocytic Leukemia.
CLL
TTFT
early stage
lymphocyte doubling time
prognosis
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2021
2021
Historique:
received:
23
03
2021
accepted:
05
07
2021
entrez:
19
8
2021
pubmed:
20
8
2021
medline:
20
8
2021
Statut:
epublish
Résumé
The prognostic role of lymphocyte doubling time (LDT) in chronic lymphocytic leukemia (CLL) was recognized more than three decades ago when the neoplastic clone's biology was almost unknown. LDT was defined as the time needed for the peripheral blood lymphocyte count to double the of the initial observed value. Herein, the LDT prognostic value for time to first treatment (TTFT) was explored in our prospective O-CLL cohort and validated in in two additional CLL cohorts. Specifically, newly diagnosed Binet stage A CLL patients from 40 Italian Institutions, representative of the whole country, were prospectively enrolled into the O-CLL1-GISL protocol (clinicaltrial.gov identifier: NCT00917540). Two independent cohorts of newly diagnosed CLL patients recruited respectively at the Division of Hematology in Novara, Italy, and at the Hospital Clinic in Barcelona, Spain, were utilized as validation cohorts. In the training cohort, TTFT of patients with LDT >12 months was significantly longer related to those with a shorter LDT. At Cox multivariate regression model, LDT ≤ 12 months maintained a significant independent relationship with shorter TTFT along with
Identifiants
pubmed: 34408978
doi: 10.3389/fonc.2021.684621
pmc: PMC8366564
doi:
Types de publication
Journal Article
Langues
eng
Pagination
684621Informations de copyright
Copyright © 2021 Morabito, Tripepi, Moia, Recchia, Boggione, Mauro, Bossio, D’Arrigo, Martino, Vigna, Storino, Fronza, Di Raimondo, Rossi, Condoluci, Colombo, Fais, Fabris, Foa, Cutrona, Gentile, Montserrat, Gaidano, Ferrarini and Neri.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The reviewer FA declared a shared affiliation with one of the authors, AN, to the handling editor at time of review.
Références
Blood. 2020 May 21;135(21):1859-1869
pubmed: 32267500
Am J Hematol. 2018 Sep;93(9):E216-E219
pubmed: 29984867
PLoS One. 2015 Mar 18;10(3):e0118801
pubmed: 25786252
J Clin Epidemiol. 2016 Nov;79:22-28
pubmed: 27181564
Ann Oncol. 2018 Apr 1;29(4):966-972
pubmed: 29365086
Clin Cancer Res. 2014 Aug 1;20(15):4141-53
pubmed: 24916701
Am J Hematol. 2013 Jul;88(7):539-44
pubmed: 23553682
Epigenetics. 2011 Feb;6(2):188-94
pubmed: 20930513
Cancer. 2019 Nov 1;125(21):3699-3705
pubmed: 31381130
Leuk Lymphoma. 2020 Jun;61(6):1512-1515
pubmed: 31992098
Clin Lymphoma Myeloma Leuk. 2020 Mar;20(3):174-183.e3
pubmed: 32033927
Genes Chromosomes Cancer. 2011 Sep;50(9):726-34
pubmed: 21638517
Leukemia. 2016 Jun;30(6):1440-3
pubmed: 26648537
Br J Haematol. 2016 Dec;175(5):983-985
pubmed: 26728120
Genes Chromosomes Cancer. 2014 Jul;53(7):612-21
pubmed: 24706380
Haematologica. 2009 Jun;94(6):887-8
pubmed: 19483161
Blood. 2014 Jul 3;124(1):49-62
pubmed: 24797299
Int J Hematol. 2014 Sep;100(3):290-5
pubmed: 25064370
Haematologica. 2020 Jun;105(6):1613-1620
pubmed: 31582547
Curr Opin Oncol. 2005 Nov;17(6):597-604
pubmed: 16224240
Can Med Assoc J. 1966 May 7;94(19):1005-10
pubmed: 4952384
Leukemia. 2020 Apr;34(4):1038-1051
pubmed: 32042081
Eur J Haematol. 2016 Jan;96(1):36-45
pubmed: 25753656
Genes Chromosomes Cancer. 2008 Sep;47(9):781-93
pubmed: 18521849
Br J Haematol. 2005 Aug;130(4):549-57
pubmed: 16098069
Blood. 2020 Apr 9;135(15):1244-1254
pubmed: 32006000
Blood. 2018 Jun 21;131(25):2745-2760
pubmed: 29540348
Nat Rev Dis Primers. 2017 Feb 09;3:17008
pubmed: 28179635
Noncoding RNA. 2020 Mar 13;6(1):
pubmed: 32182990
Nat Rev Clin Oncol. 2019 Nov;16(11):684-701
pubmed: 31278397
Br J Haematol. 2014 Jun;165(5):629-39
pubmed: 24579978
Am J Hematol. 2017 Jun;92(6):E91-E93
pubmed: 28240788
Am J Hematol. 2016 Nov;91(11):1090-1095
pubmed: 27465919
Br J Haematol. 1986 Mar;62(3):567-75
pubmed: 3954968
Am J Hematol. 2014 Jul;89(7):743-50
pubmed: 24711230
Aging Clin Exp Res. 2021 Feb;33(2):279-283
pubmed: 32240502
Br J Haematol. 2020 Jun;189(5):853-859
pubmed: 32064595
BMC Med Genomics. 2013 Sep 03;6:27
pubmed: 24004562
Diagn Progn Res. 2018 Jul 11;2:14
pubmed: 31093563
J Clin Invest. 2005 Mar;115(3):755-64
pubmed: 15711642
Hematol Oncol. 2020 Aug;38(3):406-408
pubmed: 32097987
Nephrol Dial Transplant. 2013 Aug;28(8):1975-80
pubmed: 23658248
Blood. 2008 Jun 15;111(12):5446-56
pubmed: 18216293
Cancers (Basel). 2019 Jun 26;11(7):
pubmed: 31248056
Blood. 2011 Dec 8;118(24):6353-61
pubmed: 21998207
Clin Cancer Res. 2010 Dec 1;16(23):5641-53
pubmed: 20947517
Cancer. 2013 Mar 15;119(6):1177-85
pubmed: 23224939
Br J Haematol. 2009 Jun;146(1):44-53
pubmed: 19438486
Cancer. 1987 Dec 1;60(11):2712-6
pubmed: 3677006
Sci Rep. 2020 Oct 28;10(1):18427
pubmed: 33116240
Blood. 2011 Dec 22;118(26):6904-8
pubmed: 22039264
Am J Hematol. 2013 Jan;88(1):24-31
pubmed: 23044996
Eur J Haematol. 2021 Jun;106(6):831-835
pubmed: 33662164
Br J Haematol. 2014 Oct;167(2):224-32
pubmed: 25041609
Blood Cancer J. 2016 Sep 09;6(9):e468
pubmed: 27611921
Cochrane Database Syst Rev. 2020 Jul 31;7:CD012022
pubmed: 32735048
Blood. 2016 Oct 20;128(16):2093-2095
pubmed: 27549308
Am J Hematol. 2019 Nov;94(11):1266-1287
pubmed: 31364186
Leukemia. 2021 Aug;35(8):2325-2331
pubmed: 33542480
J Clin Invest. 1998 Oct 15;102(8):1515-25
pubmed: 9788964
Genes Chromosomes Cancer. 2014 Mar;53(3):264-73
pubmed: 24347044
Eur J Haematol. 2016 Jan;96(1):72-7
pubmed: 25819739
Leuk Res. 2013 Aug;37(8):943-7
pubmed: 23499499
Haematologica. 2008 Mar;93(3):413-22
pubmed: 18287138
Br J Haematol. 2015 Feb;168(3):455-9
pubmed: 25208809
Am J Hematol. 2018 Feb;93(2):E35-E37
pubmed: 29098721